XML 78 R46.htm IDEA: XBRL DOCUMENT
v3.21.2

Material Agreements (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 2 Months Ended | 3 Months Ended | 6 Months Ended | 8 Months Ended | 17 Months Ended | 63 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 03, 2020 | Nov. 30, 2020 | Jun. 30, 2020 | Dec. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Feb. 20, 2019 | Jun. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | $ 15,345 | $ 21,675 | $ 26,467 | $ 30,440 |  |  |
License and royalty revenue |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | 2,311 | 12,928 | $ 4,672 | $ 13,354 |  |  |
Commercial Exploitation Agreement with Indivior |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
License agreement term |  |  |  |  |  |  | 7 years |  |  |  |
Automatic renewal period of agreement |  |  |  |  |  |  | 1 year |  |  |  |
Commercial Exploitation Agreement with Indivior | Minimum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Notice period of intent not to renew agreement |  |  |  |  |  |  | 1 year |  |  |  |
Supplemental Agreement with Indivior |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Contingent payments receivable in the future |  |  |  |  | 34,250 |  | $ 34,250 |  | $ 34,250 |  | $ 34,250
Revenues |  |  |  |  |  |  |  |  |  | $ 40,750 |
Supplemental Agreement with Indivior | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Contingent payments receivable in the future |  |  |  |  | 75,000 |  | 75,000 |  | 75,000 |  | 75,000
Supplemental Agreement with Indivior Performance or Event-Based Milestones |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Contingent payments receivable in the future |  |  |  |  | 33,000 |  | 33,000 |  | 33,000 |  | 33,000
Supplemental Agreement with Indivior Additional Process Patent Rights to the Company |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Contingent payments receivable in the future |  |  |  |  | 1,250 |  | 1,250 |  | 1,250 |  | 1,250
License Agreement with Sunovion Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  | 22,000
License Agreement with Sunovion Pharmaceuticals, Inc. | License and royalty revenue |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  | $ 8,000 |  |  |  |  |
License Agreement with Sunovion Pharmaceuticals, Inc Milestones |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  | 17,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones | License and royalty revenue |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  | $ 4,000 |  |  |  |
License Agreement with Sunovion Pharmaceuticals, Inc. Upfront |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  | $ 5,000
Marathon Pangolin Royalty LLC | Monetization Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Proceeds from sale of future revenue | $ 40,000 |  |  | $ 10,000 |  |  |  |  | $ 50,000 |  |
Proceeds from debt, contingent on additional milestones |  | $ 75,000 |  |  |  |  |  |  |  |  |
Marathon Pangolin Royalty LLC | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Proceeds from sale of future revenue | $ 125,000 |  |  |  |  |  |  |  |  |  |
Agreement to Terminate CLA with KemPharm | License and royalty revenue |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  | $ 500 |  | $ 2,000 |  |  |  |  |  |

X
- Definition Period for which the agreement is renewed automatically. + References No definition available. + Details
Name: | aqst_AutomaticRenewalPeriodOfAgreement
Namespace Prefix: | aqst_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent Monetization Agreement, Milestone Payment + References No definition available. + Details
Name: | aqst_ContingentMonetizationAgreementMilestonePayment
Namespace Prefix: | aqst_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential additional payment receivable under the agreement as of the balance sheet date. These are the aggregate from any combination of (a) performance or event-based milestone payments and (b) single digit percentage royalties on net revenue earned by Indivior on sales of Suboxone and earnings through the issuance of additional process patent rights to the company. + References No definition available. + Details
Name: | aqst_ContingentPaymentsReceivableInTheFuture
Namespace Prefix: | aqst_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License agreement term period. + References No definition available. + Details
Name: | aqst_LicenseAgreementTerm
Namespace Prefix: | aqst_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Notice period of intent not to renew agreement, prior to the expiration of the initial or renewal term. + References No definition available. + Details
Name: | aqst_NoticePeriodForNotToRenewAgreement
Namespace Prefix: | aqst_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds From Sale of Future Revenues, Net + References No definition available. + Details
Name: | aqst_ProceedsFromSaleOfFutureRevenuesNet
Namespace Prefix: | aqst_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=aqst_LicenseAndRoyaltyRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aqst_CommercialExploitationAgreementWithIndiviorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aqst_SupplementalAgreementWithIndiviorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aqst_SupplementalAgreementWithIndiviorPerformanceOrEventBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aqst_SupplementalAgreementWithIndiviorAdditionalProcessPatentRightsToTheCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aqst_MarathonPangolinRoyaltyLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CreditFacilityAxis=aqst_MonetizationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aqst_AgreementToTerminateCLAWithKemPharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |